ReP USP - Resultado da busca

Filtros : "Hungria" "FMRP-RCM" Removidos: "Reuniao Anual de Genetica de Microrganismos" "ECONOMIA" "Gama Rodrigues, Joaquim José" "ESTÉTICA HIST." Limpar

Filtros

USP affiliated authors
- marin neto, jose antonio (~1)
- rego, eduardo magalhães (~1)
Date published
- 2016 (~1)
- 2015 (~1)
Subjects
- colesterol (1)
- doenças cardiovasculares (1)
- doenças hematológicas (1)
- hematologia (1)
- neoplasias (1)

Collaboration
Normalized affiliation
- uppsala university (uppsala universitet) (~1)
Non normalized affiliation
- academic medical center, amsterdam (1)
- chinese academy of medical sciences, beijing (1)
- dante pazzanese institute of cardiology, são paulo (1)
- fundacion ecla, rosario (1)
- health sciences and mcmaster university, hamilton, ontario (1)

Countries of institutions of collaboration
- hungria (2)
- república tcheca (2)
- rússia (antiga urss) - federação russa (2)
- ucrânia (2)
- alemanha (1)

Artigo de periodico
Novel approaches in primary cardiovascular disease prevention: the HOPE-3 trial rationale, design, and participants' baseline characteristics (2016)
Lonn, Eva; Bosch, Jackie; Pogue, Janice; Avezum, Alvaro; Chazova, Irina; Dans, Antonio; Diaz, Rafael; Fodor, George J.; Held, Claes; Jansky, Petr; Keltai, Matyas; Keltai, Katalin; kunti, Kamlesh; Kim, Jae-Hyung; Leiter, Lawrence; Lewis, Basil; Liu, Lisheng; Lopez-Jaramillo, Patricio; Pais, Prem; Parkhomenko, Alexandr; Peters, Ron J. G; Piegas, Leopoldo S; Reid, Christopher M; Sliwa, Karen; Toff, William D; Varigos, John; Xavier, Denis; Yusoff, Khalid; Zhu, Jun; Dagenais, Gilles; Yusuf, Salim; Marin Neto, José Antonio
Source: Canadian Journal of Cardiology. Unidade: FMRP
Subjects: RECEPTORES DE ANGIOTENSINA, PRESSÃO SANGUÍNEA, DOENÇAS CARDIOVASCULARES, COLESTEROL
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
LONN, Eva et al. Novel approaches in primary cardiovascular disease prevention: the HOPE-3 trial rationale, design, and participants' baseline characteristics. Canadian Journal of Cardiology, v. 32, n. 3, p. 311-318, 2016Tradução . . Disponível em: https://doi.org/10.1016/j.cjca.2015.07.001. Acesso em: 16 nov. 2024.
APA
Lonn, E., Bosch, J., Pogue, J., Avezum, A., Chazova, I., Dans, A., et al. (2016). Novel approaches in primary cardiovascular disease prevention: the HOPE-3 trial rationale, design, and participants' baseline characteristics. Canadian Journal of Cardiology, 32( 3), 311-318. doi:10.1016/j.cjca.2015.07.001
NLM
Lonn E, Bosch J, Pogue J, Avezum A, Chazova I, Dans A, Diaz R, Fodor GJ, Held C, Jansky P, Keltai M, Keltai K, kunti K, Kim J-H, Leiter L, Lewis B, Liu L, Lopez-Jaramillo P, Pais P, Parkhomenko A, Peters RJG, Piegas LS, Reid CM, Sliwa K, Toff WD, Varigos J, Xavier D, Yusoff K, Zhu J, Dagenais G, Yusuf S, Marin Neto JA. Novel approaches in primary cardiovascular disease prevention: the HOPE-3 trial rationale, design, and participants' baseline characteristics [Internet]. Canadian Journal of Cardiology. 2016 ; 32( 3): 311-318.[citado 2024 nov. 16 ] Available from: https://doi.org/10.1016/j.cjca.2015.07.001
Vancouver
Lonn E, Bosch J, Pogue J, Avezum A, Chazova I, Dans A, Diaz R, Fodor GJ, Held C, Jansky P, Keltai M, Keltai K, kunti K, Kim J-H, Leiter L, Lewis B, Liu L, Lopez-Jaramillo P, Pais P, Parkhomenko A, Peters RJG, Piegas LS, Reid CM, Sliwa K, Toff WD, Varigos J, Xavier D, Yusoff K, Zhu J, Dagenais G, Yusuf S, Marin Neto JA. Novel approaches in primary cardiovascular disease prevention: the HOPE-3 trial rationale, design, and participants' baseline characteristics [Internet]. Canadian Journal of Cardiology. 2016 ; 32( 3): 311-318.[citado 2024 nov. 16 ] Available from: https://doi.org/10.1016/j.cjca.2015.07.001
Artigo de periodico
Florence: a randomized, double-blind, phase III pivotal study of febuxostat versus allopurinol for the prevention of tumor lysis syndrome (TLS) in patients with hematologic malignancies at intermediate to high TLS risk (2015)
Spina, M.; Nagy, Z.; Ribera, J. M.; Federico, M.; Aurer, I.; Jordan, K.; Borsaru, G.; Pristupa, A. S.; Bosi, A.; Grosicki, S.; Glushko, N. L.; Ristic, D.; Jakucs, J.; Montesinos, P.; Mayer, J.; Rego, Eduardo Magalhães; Baldini, S.; Scartoni, S.; Capriati, A.; Maggi, C. A.; Simonelli, C.
Source: Annals of Oncology. Unidade: FMRP
Subjects: NEOPLASIAS, HEMATOLOGIA, RIM, ÁCIDO ÚRICO, DOENÇAS HEMATOLÓGICAS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
SPINA, M. et al. Florence: a randomized, double-blind, phase III pivotal study of febuxostat versus allopurinol for the prevention of tumor lysis syndrome (TLS) in patients with hematologic malignancies at intermediate to high TLS risk. Annals of Oncology, v. 26, n. 10, p. 2155-2161, 2015Tradução . . Disponível em: https://doi.org/10.1093/annonc/mdv317. Acesso em: 16 nov. 2024.
APA
Spina, M., Nagy, Z., Ribera, J. M., Federico, M., Aurer, I., Jordan, K., et al. (2015). Florence: a randomized, double-blind, phase III pivotal study of febuxostat versus allopurinol for the prevention of tumor lysis syndrome (TLS) in patients with hematologic malignancies at intermediate to high TLS risk. Annals of Oncology, 26( 10), 2155-2161. doi:10.1093/annonc/mdv317
NLM
Spina M, Nagy Z, Ribera JM, Federico M, Aurer I, Jordan K, Borsaru G, Pristupa AS, Bosi A, Grosicki S, Glushko NL, Ristic D, Jakucs J, Montesinos P, Mayer J, Rego EM, Baldini S, Scartoni S, Capriati A, Maggi CA, Simonelli C. Florence: a randomized, double-blind, phase III pivotal study of febuxostat versus allopurinol for the prevention of tumor lysis syndrome (TLS) in patients with hematologic malignancies at intermediate to high TLS risk [Internet]. Annals of Oncology. 2015 ; 26( 10): 2155-2161.[citado 2024 nov. 16 ] Available from: https://doi.org/10.1093/annonc/mdv317
Vancouver
Spina M, Nagy Z, Ribera JM, Federico M, Aurer I, Jordan K, Borsaru G, Pristupa AS, Bosi A, Grosicki S, Glushko NL, Ristic D, Jakucs J, Montesinos P, Mayer J, Rego EM, Baldini S, Scartoni S, Capriati A, Maggi CA, Simonelli C. Florence: a randomized, double-blind, phase III pivotal study of febuxostat versus allopurinol for the prevention of tumor lysis syndrome (TLS) in patients with hematologic malignancies at intermediate to high TLS risk [Internet]. Annals of Oncology. 2015 ; 26( 10): 2155-2161.[citado 2024 nov. 16 ] Available from: https://doi.org/10.1093/annonc/mdv317

Digital Library of Intellectual Production of Universidade de São Paulo 2012 - 2024